Related Experiment Video
Updated: Jul 17, 2025

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
Dissecting the effects of METTL3 on alternative splicing in prostate cancer
Lin Wang1,2, Ling Shi2, Yonghao Liang2
1Metabolic Disease Research Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Abstract:
Although the role of METTL3 has been extensively studied in many cancers, its role in isoform switching in prostate cancer (PCa) has been poorly explored. To investigate its role, we applied standard RNA-sequencing and long-read direct RNA-sequencing from Oxford Nanopore to examine how METTL3 affects alternative splicing (AS) in two PCa cell lines. By dissecting genome-wide METTL3-regulated AS events, we noted that two PCa cell lines (representing two different PCa subtypes, androgen-sensitive or resistant) behave differently in exon skipping and intron retention events following METTL3 depletion, suggesting AS heterogeneity in PCa. Moreover, we revealed that METTL3-regulated AS is dependent on N6-methyladenosine (m6A) and distinct splicing factors. Analysis of the AS landscape also revealed cell type specific AS signatures for some genes (e.g., MKNK2) involved in key functions in PCa tumorigenesis. Finally, we also validated the clinical relevance of MKNK2 AS events in PCa patients and pointed to the possible regulatory mechanism related to m6A in the exon14a/b region and SRSF1. Overall, we characterize the role of METTL3 in regulating PCa-associated AS programs, expand the role of METTL3 in tumorigenesis, and suggest that MKNK2 AS events may serve as a new potential prognostic biomarker.
Insights
METTL3 regulates alternative splicing (AS) in prostate cancer (PCa) by affecting exon skipping and intron retention. METTL3-dependent AS events, influenced by N6-methyladenosine (m6A), highlight MKNK2 AS events as potential PCa biomarkers.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- METTL3's role in cancer is known, but its function in prostate cancer (PCa) isoform switching via alternative splicing (AS) remains understudied.
- Prostate cancer exhibits significant heterogeneity, with androgen-sensitive and resistant subtypes potentially displaying distinct molecular mechanisms.
Purpose of the Study:
- To investigate the role of METTL3 in regulating alternative splicing (AS) in prostate cancer (PCa).
- To explore the impact of METTL3 depletion on AS events in different PCa subtypes.
- To identify potential prognostic biomarkers associated with METTL3-regulated AS in PCa.
Main Methods:
- Utilized standard RNA-sequencing and long-read direct RNA-sequencing (Oxford Nanopore).
- Analyzed genome-wide METTL3-regulated alternative splicing events in two distinct PCa cell lines.
- Investigated the dependence of METTL3-regulated AS on N6-methyladenosine (m6A) and splicing factors.
Main Results:
- METTL3 depletion induced differential AS events (exon skipping, intron retention) in androgen-sensitive versus resistant PCa cell lines, indicating AS heterogeneity.
- METTL3-regulated AS is dependent on m6A modification and specific splicing factors.
- Identified cell type-specific AS signatures for genes like MKNK2, crucial for PCa tumorigenesis.
- Validated the clinical relevance of MKNK2 AS events in PCa patients, suggesting an m6A-mediated regulatory mechanism involving SRSF1.
Conclusions:
- METTL3 plays a significant role in regulating PCa-associated alternative splicing programs.
- The findings expand the understanding of METTL3's function in tumorigenesis.
- MKNK2 alternative splicing events represent a promising novel prognostic biomarker for prostate cancer.
Related Concept Videos
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
MicroRNAs
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
What is Gene Expression?

